VR Pupillometry in Cognitive Impairment

Recruiting Observational Study
Alzheimer s Disease Major Depressive Disorder (MDD) Mild Cognitive Impairment Dementia
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 80
Sex
Any
Study type
Observational
Participants needed
140 (estimated)
Sponsor
Max-Planck-Institute of Psychiatry · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important. This prospective, single-center, repeated-measures study evaluates whether VR-based eye-tracking pupillometry can provide a practical, non-invasive biomarker of cognitive impairment and its progression over time. Pupil responses are linked to …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Written informed consent. 2. Age 18-80 years. 3. Ability to read and understand German. 4. For patient cohorts: suspected or confirmed diagnosis of AD/MCI/depressive disorder with cognitive impairment according to clinical assessment and routine documentation. Exclusion Crit…
Contacts

Eva Vidovic, MD

089-30622-1402

eva_vidovic@psych.mpg.de

CONTACT

Victor I. Spoormaker, PhD

089-30622-1402

ambulanz@psych.mpg.de

CONTACT